Depressive disorder associated with mycophenolate mofetil

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 136-139

  Draper, Heather M ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Adverse drug reactions; Depression; Immunosuppression; Immunosuppressive agents; Myasthenia gravis; Mycophenolate mofetil

Indexed keywords

CLONAZEPAM; CYCLOSPORIN; FLUOXETINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUETIAPINE; RAPAMYCIN; SERTRALINE; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANXIETY DISORDER; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; POSTMARKETING SURVEILLANCE;

DEPRESSIVE DISORDER; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID;

EID: 38049051869     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.136     Document Type: Article

References (24)

1. Moons P, De Geest S, Abraham I, Van Cleemput J, Vanhaecke J. Symptom experience associated with maintenance immunosuppression after heart transplantation: patient's appraisal of side effects. Heart Lung 1998;27:315-25.
2. Rosenberger J, Madarasova Geckova A, van Dijk JP, Roland R, van de Heuvel WJA, Groothoff JW. Factors modifying stress from adverse effects of immunosuppressive medication in kidney transplant recipients. Clin Transplant 2005;19:70-6.
3. van der Molen LR, van Son WJ, Tegzess AM, Stegeman CA. Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathy. Nephrol Dial Transplant 1999;14:998-1000.
4. Roche Laboratories Inc. Cellcept (mycophenolate mofetil) package insert. Nutley NJ; 2005.
5. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
6. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-7.
7. Fisher J, Parkinson K, Kothari MJ. Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromusc Dis 2003;4:105-8.
8. Stewart SB, Robertson KR, Johnson KM, Howard JF. The prevalence of depression in myasthenia gravis. J Clin Neuromusc Dis 2007;8:111-15.
9. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2004;43:361-94.
10. Dew MA, Kormos RL, DiMartini AF, et al. Prevalence and risk of depression and anxiety-related disorders during the first year after heart transplantation. Psychosomatics 2001;42:300-13.
11. Hricik DE, Halbert RJ, Barr ML, et al. Life satisfaction in renal transplant recipients: preliminary results from the transplant learning center. Am J Kidney Dis 2001;38:580-7.
12. Kemper MJ, Spartà G, Laube GF, Miozzari M, Neuhaus TJ. Neuropsychologic side effects of tacrolimus in pediatric renal transplantation. Clin Transplant 2003;17:130-4.
13. Sredl D, Werner T, Springhart D, Watkins D, Shaner M, McBride G. An evidence-based pilot study exploring relationships between psychologic and physiologic factors in post-lung-transplant adolescents with cystic fibrosis. J Pediatr Nurs 2003;18:216-20.
14. Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Medpysch drug-drug interactions update: immunosuppressants. Psychosomatics 2004;45:354-60.
15. Novartis Pharmaceuticals Corporation. Neoral (cyclosporine) package insert. East Hanover, NJ; 2005.
16. Wyeth Pharmaceuticals Inc. Rapamune (sirolimus) package insert. Philadelphia, PA; 2006.
17. Astellas Pharma US, Inc. Prograf (tacrolimus) package insert. Deerfield, IL; 2006.
18. Patten SB, Love EJ. Can drugs cause depression? A review of the evidence. J Psychiatry Neurosci 1993;18:92-102.
19. Patten SB. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004;73:207-15.
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry 2001;6:277-94.
22. Koh KB. Emotion and immunity. J Psychosom Res 1998;45:107-15.
23. Irwin M. Immune correlates of depression. Adv Exp Med Biol 1999;461:1-24.
24. Fricchione G, Daly R, Rogers MP, Stefano GB. Neuroimmunologic influences in neuropsychiatric and psychophysiologic disorders. Acta Pharmacol Sin 2001;22:577-87.